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Background: The objective of this study was to measure health-related quality of life (HRQL) 
in outpatients with chronic obstructive pulmonary disease (COPD) and to assess differences in 
HRQL according to age, gender, and severity of COPD.
Methods: A total of 9405 patients (79% men, mean age 68 years) participated in a cross-
sectional study. HRQL was measured with the Short Form 12 Health Survey Questionnaire 
(SF-12). Severity of COPD was graded into three levels according to forced expiratory volume 
in one second value.
Results: COPD severity was mild in 33.8% of cases, moderate in 49.3% and severe in 16.8%. The 
mean physical component summary (PCS-12) and mental component summary (MCS-12) scores 
were 36.8 ± 10.4 and 47.2 ± 11.2, respectively. General health and physical functioning domains 
were those with the lowest scores. The mean MCS-12 scores were signiﬁ  cantly higher in men 
(47.9 ± 10.9) than in women (44.1 ± 11.8) (P   0.001). Patients older than 60 years rated HRQL 
worse than patients aged 40–59 years. There were statistically signiﬁ  cant differences according 
to severity of disease in the mean scores of all domains of the PCS-12 and MCS-12 scales.
Conclusions: The present ﬁ  ndings show the inﬂ  uence of female gender, older age and moderate-
to-severe of airﬂ  ow limitation on HRQL in outpatients with COPD attended in daily practice.
Keywords: health status, health surveys, multicenter study, pulmonary disease, chronic 
obstructive/epidemiology, quality of life, questionnaires
Introduction
Chronic obstructive pulmonary disease (COPD) is a debilitating multicomponent 
respiratory condition primarily affecting the airway and lung parenchyma but also 
inducing a variety of extrapulmonary consequences, such as systemic inﬂ  ammation, 
nutritional abnormalities, weight loss, skeletal muscle dysfunction and additional organ 
effects (Decramer et al 2005). The high burden of COPD resulting from cough, sputum 
production and shortness of breath, is further contributed to by systemic effects, lead-
ing to a pronounced deterioration in health status and a diminished quality of life. It 
has been largely recognized that COPD is a public health problem worldwide and a 
major cause of chronic morbidity and mortality (Chan-Yeung et al 2004; Pauwels and 
Rabe 2004; Manino 2005). COPD is a highly prevalent disease, and it is estimated that 
7%–10% of the adult population may be affected (Sobradillo-Peña 2000; Halbet et al 
2003, 2006). In spite of antismoking campaigns, the prevalence and mortality rates of 
COPD continue to rise every year. It has been shown that COPD is the most rapidly 
increasing cause of death in individuals older than 65 years of age, which represents 
the most rapidly growing segment of the population in developed countries. Disability 
from COPD is expected to rise by 2020 with aging of the population and the increase 
in disease prevalence (Weiss et al 2003).
Health-related quality of life (HRQL) in COPD patients has received an increasing 
interest over the past decade. An impaired health status is a risk factor for frequent International Journal of COPD 2008:3(4) 684
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exacerbations and hospital admissions (Miravitlles et al 
2006). Previous studies using both generic and disease-
speciﬁ  c instruments for measuring HRQL in COPD patients 
(Mahler 2000) have shown relationships between HRQL and 
disease severity, respiratory symptoms, gender, comorbidity, 
body weight, upper airway symptoms, and psychological 
status (Hajiro et al 2000; Wijnhoven et al 2003; Peruzza et al 
2003; Hurst et al 2004; Katsura et al 2005; Ståhl et al 2005; 
de Torres et al 2006). In a recent study carried out in Spain, 
determinants of HRQL in patients with COPD followed in 
primary care included sex, forced expiratory volume in one 
second (FEV1), use of oxygen therapy, and number of visits 
to emergency rooms and hospital admissions (Carrasco 
Garrido et al 2006).
In order to provide further information on HRQL in 
patients with COPD, a multicenter cross-sectional study was 
designed, the primary objectives of which were to collect 
information on HRQL in a large sample of outpatients with 
COPD visited by family physicians and pneumologists in 
actual conditions of the daily practice and to determine 
whether there were differences in HRQL according to 
age, gender, and severity of COPD. Secondary objectives 
included to assess the correlation between quality of life 
perceived by COPD patients and functional status (FEV1) 
and level of dyspnea, and to determine health care resources 
consumption.
Methods
Study design
The VICE Study (Spanish acronym of Living with 
Chronic Obstructive Pulmonary Disease) was a 2-month 
(April–May 2004) cross-sectional survey of the ﬁ  rst ﬁ  ve 
consecutive patients with COPD in the outpatient setting 
seen by general practitioners in primary care centers and 
pneumologists in the outpatients clinics of the Services of 
Pneumology of acute care hospitals from all over Spain. 
A sample of 2300 general practitioners and 200 pneumolo-
gists were recruited using a stratiﬁ  ed random sample drawn 
from the list of registered physicians in all autonomous 
communities. Physicians were eligible for inclusion if they 
were actively practicing in Spain, reported spending at least 
50% of their time in direct patient care and had a primary 
specialty in family practice or pneumology. Physicians 
participated voluntarily in the study and did not receive 
any payment.
The study protocol was approved by the Ethics Committee 
of hospital Gregorio Marañón, Madrid (Spain), and written 
informed consent was obtained from all participants.
Patients
Patients of both sexes, aged 40 years or older, with a previous 
diagnosis of COPD (conﬁ  rmed by history and spirometry) 
were eligible provided that the reason of consultation was 
related to his/her pulmonary condition. The diagnosis of 
the disease was performed according to the criteria of the 
Spanish Society of Pneumology and Chest Surgery (SEPAR) 
based on the demonstration, through a forced spirometry, of 
a FEV1 below 80% of the reference value and a FEV1/forced 
vital capacity (FVC) ratio below 0.7 after the bronchodila-
tion test. The severity of COPD was graded according to the 
FEV1 value: mild (FEV1 60%–80% of the reference value), 
moderate (FEV1 40%–59% of the reference value) and severe 
(FEV1   40% of the reference value) following SEPAR 
criteria (Barberà et al 2001), which are based on the guide-
lines of the British Thoracic Society (BTS 1997). Spirometric 
measurements at the time of the study were not performed.
Patients with an acute worsening of their COPD in the 
previous month were excluded as were those suffering 
from any physical and/or psychiatric disease precluding to 
complete the HRQL questionnaire. Patients with more than 
80% of missing data for the study variables in their medical 
records were also excluded.
Data collection
Interviews were carried out by the participating physician 
during the course of the patient’s consultation in routine 
daily practice. All data were collected in a single visit using a 
questionnaire in which the following variables were recorded: 
age; sex; height; weight; smoking habit (current smoker, 
never smoker, ex-smoker); year of COPD diagnosis; data of 
the last spirometric measurement and FEV1 and FEV1/FVC 
values; severity of COPD; current COPD therapy including 
nonpharmacological management (smoking cessation coun-
seling, stop smoking treatment, oxygen therapy, rehabilita-
tion, others) and pharmacological treatment (short-acting 
β2-agonists, long-acting β2-agonists, short-acting anticho-
linergics, long-acting anticholinergics, inhaled steroids, 
oral steroids, a ﬁ  xed combination of anticholinergics and 
short-acting β2-agonists, a ﬁ  xed combination of long-acting 
β2-agonists and inhaled steroids, antibiotics, others); dis-
ability; and health resources utilization in the previous 
12 months (number of outpatient visits to either the primary 
care physician and the pneumologist, emergency department 
visits, hospitalizations, and days on sick leave).
Disability was classified according to the Medical 
Research Council (MRS) dyspnea scale (Bestall et al 1999). 
The MRC dyspnea scale concerns perceived breathlessness International Journal of COPD 2008:3(4) 685
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and consists of ﬁ  ve degrees: 1, “shortness of breath with 
strenuous exercise”; 2, “shortness of breath when hurrying”; 
3, “walking slower than people of the same age on the level 
ground or stop for breath while walking at own pace on the 
level ground”; 4, “needing to stop after 100 yards on the level 
ground”; 5, “too breathless to leave the house”. A Spanish 
translation of MRC dyspnea scale was administered to the 
subjects (Gallego et al 2002).
Health status
All patients were administered the Short Form 12 Health 
Survey Questionnaire (SF-12), an abbreviated version of the 
SF-36 health questionnaire that contains 12 items (Ware 
et al 1996). These 12 items explain more than 90% of the 
variance of the physical and mental component scales of 
the SF-36. From them two scores can be calculated, the physi-
cal (PCS-12) and the mental (PCS-12) component summary, 
using a value of 50 with a standard deviation of 10 as reference 
population. In this study, the general Spanish adult population 
has been used as reference (Alonso et al 1998a; Vilagut et al 
2005). Scores range from 0 to 100, with higher scores repre-
senting better HRQL. A score  60 has been regarded as high 
HRQL, 40−60 as normal HRQL, and  40 as impaired (low) 
HRQL. A translated version of the questionnaire validated 
for Spain has been used (Alonso et al 1998b).
Statistical analysis
In order to detect a clinically relevant differences of 5 points 
in the mean PCS-12 and MCS-12 scores among the subgroups 
of men and women stratiﬁ  ed by the three severity levels of 
COPD with a statistical power of 95% and a level of statistical 
signiﬁ  cance (alpha) of 0.05, using a two-tailed Student’s t test 
for the comparison of two groups (considering a standard 
deviation of 12 for the mean SF-12 scores of each group), a 
total number of patients required in each stratum was 165. 
According to data of the IBERPOC study (Sobradillo et al 
1999; Villasante Fernandez-Montes et al 1999), women 
showed the lowest prevalence of COPD (22%) with the 
subset of women with severe disease accounting for 1.653% 
of the total number of patients with COPD. Therefore, the 
total number of patients required was 9981 (165/0.01653). 
This number was increased to 12,477 assuming losses of 
patients due to nonevaluable cases of 20%.
The Statistical Package for the Social Sciences (version 
12.0; SPSS Inc., Chicago, IL) was used for the analysis of 
data. Double data entry was carried out with a subsequent 
validation to guarantee the quality and consistency of the 
data. Continuous variables are expressed as mean and 
standard deviation (SD) or median and ranges (25th−75th 
percentiles). Qualitative variables are described as frequency 
and percentages. Conﬁ  dence intervals (CIs) were calculated 
at the 95% level. Differences of HRQL in the subgroups of 
patients according to gender and severity of COPD were 
analyzed with the paired Student’s t test. The Spearman’s 
rank-order correlation coefﬁ  cient (ρ) was calculated to 
assess the relationship between HRQL and FEV1 and level 
of dyspnea. The chi-square (χ2) test was used to assess differ-
ences in health resources utilization among the study groups. 
Statistical signiﬁ  cance was set at P   0.05.
Results
The number of physicians participating in the study was 2144 
(general practitioners, n = 1826; pneumologists, n = 240), 
which enabled a recruitment total of 10,782 patients. How-
ever, 1377 patients (12.8%) were excluded due to missing 
data in the patient’s medical history (n = 831) and lack of 
fulﬁ  llment of the selection criteria (n = 546).
The study population included 9405 patients (79.7% men, 
20.3% women) with a mean (±SD) age of 67.8 ± 9.8 years. 
Sociodemographic and clinical characteristics of the patients 
are shown in Table 1. Salient features were as follows: 69% of 
patients were found in the 60−79 year stratum, 77% had a body 
mass index (BMI)   25 kg/m2, 61% were ex-smokers (median 
of 10 years since smoking cessation) and 22.6% were current 
smokers (median pack-years 40) and had been smoking for 
a mean of 36.7 ± 13.6 years. Patients had a long-standing 
COPD, with a mean time since diagnosis of 10 years.
With regard to the last spirometric measurement, the mean 
FEV1 value was 55.1 ± 14.3%. The severity of disease was 
mild in 33.8% of cases, moderate in 49.3% and severe in 
16.8%. There were differences in COPD severity according 
to gender, with signiﬁ  cantly higher percentages of men com-
pared to women with moderate (50.4% vs 45.4%) and severe 
(18.0% vs 10.7%) disease (P   0.001). 40.8% of patients 
aged 40−50 years suffered from moderate or severe COPD 
as opposed to 76.1% of patients of 80 years of age or older 
(P   0.001). Most patients (46%) had a moderate degree of 
dyspnea (MRC category 2). However, 14.5% of men showed 
a moderately severe degree of dyspnea (MRC categories 4 
and 5) compared with 13.7% of women. The degree of dys-
pnea also increased with age, with 3.4% of patients aged 
40−50 years in the MRC categories 4 and 5 compared with 
29.2% of patients aged 80 years or older (P   0.001).
The mean PCS-12 and MCS-12 scores were 36.8 ± 10.4 
and 47.2 ± 11.2, respectively. General health and physical 
functioning domains were those with the lowest scores, International Journal of COPD 2008:3(4) 686
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Table 1 Sociodemographic and clinical characteristics of patients
Characteristic Number (%) Mean ± SD (range)*
Total no of patients 9405
Age, years (n = 9095) 67.8 ± 9.8 (61−75)
Age groups (n = 8744)
40−49 years 405 (4.6)
50−59 years 1324 (15.1)
60−69 years 2932 (33.5)
70−79 years 3120 (35.7)
 80 years 963 (11.1)
Sex (n = 8808)
Men 7022 (79.7)
Women 1786 (20.3)
Height cm mean (SD) (n = 9124) 166.1 ± 7.7 (161−171)
Weight kg. mean (SD) (n = 9017) 76.3 ± 12.1 (69−84)
Body mass index (BMI) (n = 8930)
 25 kg/m2 2090 (23.4)
25–29 kg/m2 4677 (52.4)
30–34 kg/m2 1735 (19.4)
35–39 kg/m2 341 (3.8)
 40 kg/m2 87 (1.0)
Smoking (n = 9347)
Never 1500 (16.0)
Ex-smoker 5737 (61.4)
Current smoker 2110 (22.6)
Years since COPD diagnosis (n = 7157) 9.7 ± 7.9
FEV1 % predicted (n = 7214) 55.1 ± 14.3 (45−66)
FEV1/FVC % (n = 5850) 61.6 ± 14.4 (52−70)
Severity of COPD (n = 9049)
Mild 3062 (33.8)
Moderate 4464 (49.3)
Severe 1523 (16.8)
MRC dyspnea scale (n = 9211)
1 1353 (14.7)
2 4237 (46.0)
3 2293 (24.9)
4 1018 (11.1)
5 310 (3.4)
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; MRC, Medical Research Council; 
SD, standard deviation.
Note: *25th–75th percentile.
whereas role emotional and social functioning domains were 
those with the highest scores (Table 2). According to results 
of the SF-12 questionnaire, HRQL was graded as normal 
(40−60 points) by 61% of patients and low ( 40 points) 
by 39% of patients. However, a higher percentage of 
patients scored less than 40 points in the physical health 
domain compared with the mental health domain (60.2% vs 
25.7%) (Table 2). As compared to the reference population, 
patients with COPD had a reduction of HRQL, with a mean 
of −1.32 ± 1.04 for PCS-12 and −0.28 ± 1.12 for MCS-12.
When HRQL in men and women was compared, there 
were no signiﬁ  cant differences in the mean PCS-12 scores International Journal of COPD 2008:3(4) 687
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(36.9 ± 10.4 vs 36.5 ± 10.3) but the mean MCS-12 scores 
were signiﬁ  cantly higher in men (47.9 ± 10.9) than in women 
(44.1 ± 11.8) (P   0.001). Scores for the different domains 
of PCS-12 and MSC-12 according to gender are shown 
in Figure 1. As compared with the reference population, 
the mean reduction of HRQL for the mental domain was 
signiﬁ  cantly higher in women (−0.59 ± 1.18) than in men 
(−0.20 ± 1.09) (P   0.001).
As shown in Table 3, the physical domain was 
scored  40 points by a signiﬁ  cantly higher percentage of 
patients compared with the mental domain for all age strata. 
On the other hand, the percentage of patients considering that 
their HRQL in the physical domain was normal or high was 
also signiﬁ  cantly lower than for the mental domain. Patients 
older than 60 years of age rated HRQL worse than patients 
in the 40−59 year age group.
In relation to COPD severity, a signiﬁ  cantly higher 
percentage of patients with mild disease rated HRQL as 
normal compared with patients with severe disease (physical 
domain 61.3% vs 18.5%; mental domain 75.9% vs 53.5%; 
P   0.001) (Table 3). The mean PCS-12 scores were 
42.4 ± 9.5 in patients with mild disease, 35.2 ± 9.5 in those 
with moderate COPD and 30.6 ± 9.5 in those with severe 
disease (P   0.001); the corresponding ﬁ  gures for the mean 
MCS-12 scores were 49.1 ± 10.1, 47.0 ± 11.1 and 43.9 ± 13.0 
in the groups of mild, moderate and severe COPD, respec-
tively. There were statistically signiﬁ  cant differences accord-
ing to severity of disease in the mean scores of all domains 
of the PCS-12 and MCS-12 scales (Figure 2). Moreover, 
patients with severe COPD showed a signiﬁ  cantly higher 
reduction of HRQL for both the physical (–1.94 ± 0.95) and 
mental domains (–0.61 ± 1.30) than patients with moderate 
or mild COPD as compared with the reference population.
HRQL correlated signiﬁ  cantly with FEV1 in both PCS-12 
(ρ = 0.313, P   0.001) and MCS-12 (ρ = 0.101, P   0.001) 
scales. As expected, an inverse significant correlation 
between HRQL and degree of dyspnea in the PCS-12 
(ρ = –0.599, P   0.001) and the MCS-12 (ρ = −0.237, 
P   0.001) scales was observed.
In relation to utilization of health resources, patients with 
severe COPD had more visits to the primary care center in 
the previous 12 months than those with mild to moderate 
COPD (5.8, 4.6 and 3.2, respectively, P   0.001). They were 
also in the emergency department more often (2.5, 1.6 and 
0.9, respectively, P   0.001). Patients with severe COPD 
had longer hospital stays (16.7 days) when compared to 
Table 2 Quality of life in patients with COPD
SF-12 questionnaire Mean ± SD No patients (%)
Physical component summary (PCS-12) 36.8 ± 10.4
Mental component summary (MCS-12) 47.2 ± 11.2
SF-12 scales
Physical functioning 38.6 ± 32.1
Role physical 44.8 ± 46.1
Bodily pain 64.3 ± 29.4
General health 30.9 ± 19.5
Vitality 43.4 ± 26.7
Social functioning 65.9 ± 27.1
Emotional role 73.1 ± 41.5
Mental health 63.1 ± 20.8
Physical domain (n = 9,405)
High ( 60 points) 26 (0.3)
Normal (40–60 points) 3714 (39.5)
Low ( 40 points) 5665 (60.2)
Mental domain (n = 9,405)
High ( 60 points) 613 (6.5)
Normal (40–60 points) 6373 (67.8)
Low ( 40 points) 2419 (25.7)
Abbreviations: COPD, chronic obstructive pulmonary disease; SD, standard deviation; SF-12, Medical Outcomes Study Short Form 12 Health Survey Questionnaire.International Journal of COPD 2008:3(4) 688
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Figure 1 Mean scores of the physical component summary (PCS-12) (upper panel) and the mental component summary (MCS-12) (lower panel) in COPD patients according 
to gender (*statistically signiﬁ  cant differences, P   0.001).
those with moderate (10.9 days) or mild disease (8.8 days) 
(P   0.001) as well as a more days on sick leave (51.2, 29.4 
and 18.9, respectively, P   0.001).
Details of nonpharmacological and pharmacological 
treatment according to HRQL and severity of COPD are sum-
marized in Table 4. Anti-smoking treatment was recorded ino 
nly 4% of patients, and even in a lower percentage of patients 
(3.6%) with severe COPD. More than 80% of patients were 
receiving pharmacological treatment (bronchodilators in 
73.7%, ﬁ  xed combinations in 57.5% and steroids in 19.8%). 
Long-acting β2-agonists were given to 42% of patients. When 
patients were stratiﬁ  ed according to normal or low HRQL, 
a signiﬁ  cantly higher percentage of patients with low HRQL 
received any modality of pharmacological treatment except 
for long-acting anticholinergics. In addition, a signiﬁ  cantly 
higher percentage of patients with severe COPD received 
any of medication as compared with those with mild and 
moderate severity of disease.
Discussion
The use of HRQL measures in COPD has currently achieved 
widespread acceptance (Domingo-Salvany et al 2002). 
However, HRQL measures have shown an inconsistent 
relationship with clinical and functional components of the 
disease. The objective of this study was to assess HRQL in 
a large population of COPD patients during the patients’ 
routine care in the outpatient setting. A generic quality of 
life questionnaire, the SF-12 that enables to calculate the International Journal of COPD 2008:3(4) 689
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physical well-being and the mental-well being components 
of HRQL was administered to all patients. This instrument 
has been shown to be a valid evaluation tool with excellent 
measurement properties in patients with chronic respiratory 
conditions, such as COPD and asthma (Katz et al 2000; 
Garratt et al 2000; Miravitlles et al 2002, 2004).
In general, most patients perceived that their HRQL 
was not impaired by COPD, although the physical health 
domain was rated poorly than the mental health domain, 
with general health, physical functioning, role physical and 
vitality showing lowers scores than the domains of mental 
health, emotional role, social functioning and bodily pain. 
Lower scores for the PCS-12 component than for the MSC-12 
component in patients with COPD have been also reported by 
others (Ståhl et al 2005; Carrasco Garrido et al 2006).
In agreement with previous reports (Peruzza et al 2003; 
de Torres et al 2006; Carrasco Garrido et al 2006), the 
present ﬁ  ndings conﬁ  rm the effect of age, gender and stage 
of disease on HRQL in patients with COPD. It has been 
shown that COPD is a main cause of severe deterioration 
of quality of life in elderly subjects and that the degree of 
this impairment mainly depends on the severity of airway 
obstruction (Peruzza et al 2003). In our study, patients older 
than 60 years of age, particularly those in the 70−79-year-old 
group, perceived that their HRQL was more affected by 
COPD than younger patients. However, in the age stratum 
of very old patients ( 80 years), a lower percentage of sub-
jects considered that their quality of life for the physical and 
mental health domains was low as compared with patients 
aged 70 to 79 years. This observation may be related to that 
fact that the oldest elderly population tend to restrict their 
own daily activities and expectations.
Compared with men, women had worse scores in all 
domains of mental health and in the role of physical and 
bodily pain of the physical health domain. Taking into 
account that a signiﬁ  cantly percentage of men had moder-
ate and severe COPD, this observation is clinically relevant 
as indicating that women with COPD develop symptoms 
inﬂ  uencing HRQL with less degree of obstruction than 
men. Unfortunately, a better characterization of our female 
population is not feasible given that other factors, such as 
socioeconomic status, education level, working status or 
co-morbidity were not evaluated. However, our results are 
in-line with those reported by de Torres and colleagues 
(2006) in a FEV1-matched case series study of 73 consecutive 
women and 73 men. These authors speculate that the factors 
affecting HRQL differ by gender at least in early stages of 
the disease and that the perceived expression of the disease is 
different between genders. In the study of Antonelli-Incalzi 
and colleagues (2003) in which differences in health status 
according to the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) criteria was evaluated, female sex 
was also associated with a greater impact of COPD on the 
health status.
In our study, like others (Ferrer et al 1997; Hajiro et al 
2000) disease severity (based on FEV1) inﬂ  uenced signiﬁ  -
cantly HRQL among subjects with COPD. Therefore, staging 
criteria for COPD based on percentage of predicted FEV1 
separated groups of patients with varying degrees of impair-
ment in HRQL. Contrary to expectations, even patients with 
Table 3 Differences in HRQL according to age and severity of COPD
Variable Physical domain Mental domain
High
 60 points
Normal 
40–60 points
Low 
 40 points
High 
 60 points
Normal 
40–60 points
Low 
 40 points
Age groups, years
40−49 (n = 2193) 10 (0.5) 1112 (50.7) 1071 (48.8) 145 (6.6) 1546 (70.5) 502 (22.9)
50−59 (n = 1990) 3 (0.2) 742 (37.3) 1245 (62.6) 131 (6.6) 1384 (69.5) 475 (23.9)
60−69 (n = 1382) 2 (0.1) 439 (31.8) 941 (68.1) 80 (5.8) 914 (66.1) 388 (28.1)
70−79 (n = 519) 2 (0.4) 139 (26.8) 378 (72.8) 25 (4.8) 330 (63.6) 164 (31.6)
 80 (n = 1073) 2 (0.2) 344 (32.1) 727 (67.8) 79 (7.4) 678 (63.2) 316 (25.9)
COPD severity
Mild (n = 3062) 16 (0.5) 1876 (61.3) 1170 (38.2) 179 (5.8) 2323 (75.9) 560 (18.3)
Moderate (n = 4464) 9 (0.2) 1425 (31.9) 3030 (67.9) 284 (6.4) 3000 (67.2) 1180 (26.4)
Severe (n = 1523) 1 (0.1) 282 (18.5) 1240 (81.4) 130 (8.5) 815 (53.5) 578 (38.0)
Abbreviations: COPD, chronic obstructive pulmonary disease; HRQOL, health-related quality of life.
Note: Percentages in parenthesis.International Journal of COPD 2008:3(4) 690
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mild disease showed substantially compromised HRQL. 
Additionally, the importance of dyspnea causing patients 
with COPD to reduce their activities of daily living (Reardon 
et al 2006) is also demonstrated in our study, with dyspnea 
showing a stronger correlation with HRQL than FEV1.
A remarkable ﬁ  nding was that 22.6% of COPD patients 
were current smokers but only 4% of the total population 
was receiving smoking cessation treatment. In a survey 
of 11,973 COPD patients carried out in Spain, 35% of 
them continued smoking (Viejo-Bañuelos et al 2006). 
Our patients had been smoking for about 40 years and the 
median pack-years was 40. Effective intervention strategies 
directed to quit smoking in COPD patients are mandatory. 
With regard to pharmacological treatment, bronchodilators, 
ﬁ  xed combinations and steroids were the most frequently 
used medications. Anticholinergics were used by 58.5% of 
the patients followed by β2-agonists (50%), theophylline 
(21.4%), inhaled steroids (15.9%) and oral steroids (7.5%). 
High dose inhaled corticosteroids in patients with moderate 
to severe chronic obstructive pulmonary disease has been 
associated with a reduced rate of decline in health status 
(Burge et al 2000). Finally, we also found a strong relation-
ship between health-care resource utilization and severity of 
disease (Hilleman et al 2000).
Our study had some limitations. A generic questionnaire 
was used to measure HRQL, which is less sensitive than 
the speciﬁ  c tools. The cross-sectional design of the study 
limits our ability to describe how progression of disease 
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Figure 2 Mean scores of the physical component summary (PCS-12) (upper panel) and the mental component summary (MCS-12) (lower panel) in COPD patients according 
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Table 4 Management of patients with COPD: nonpharmacological and pharmacological treatment in the previous 12 months
Management Total 
population 
(n = 9405)
Health-related quality of life Severity of COPD
Normal 
(n = 5747)
Low 
(n = 3658)
P value Mild 
(n = 3062)
Moderate 
(n = 4464)
Severe 
(n = 1523)
P value
Nonpharmacological 
therapy
4479 (47.6) 2568 (44.7) 1911 (52.2) 0.001 1313 (42.9) 2134 (47.8) 892 (58.6) 0.001
Smoking cessation 
counseling
2263 (24.1) 1450 (25.2) 813 (22.2) 0.001 811 (26.5) 1032 (23.1) 355 (23.3) 0.002
Stop smoking 
treatment
385 (4.1) 239 (4.2) 146 (4.0) 0.689 136 (4.4) 184 (4.1) 55 (3.6) 0.411
Oxygen therapy 813 (8.6) 235 (4.1) 578 (15.8) 0.001 47 (1.5) 305 (6.8) 434 (28.5) 0.001
Rehabilitation 947 (10.1) 457 (8.0) 490 (13.4) 0.001 194 (6.3) 500 (11.2) 233 (15.3) 0.001
Pharmacological 
treatment
7980 (84.8) 4727 (82.3) 3253 (88.9) 0.001 2416 (78.9) 3872 (86.7) 1391 (91.3) 0.001
Bronchodilators 6935 (73.7) 4176 (72.7) 2759 (75.4) 0.003 2123 (69.3) 3319 (74.4) 1232 (80.9) 0.001
Short-acting 
β2-agonists
2539 (27.0) 1449 (25.2) 1090 (29.8) 0.001 747 (24.4) 1181 (26.5) 510 (33.5) 0.001
Long-acting 
β2-agonists
2167 (23.0) 1283 (22.3) 884 (24.2) 0.038 589 (19.2) 1059 (23.7) 424 (27.8) 0.001
Short-acting 
anticholinergics
1552 (16.5) 900 (15.7) 652 (17.8) 0.005 414 (13.5) 765 (17.1) 316 (20.7) 0.001
Long-acting 
anticholinergics
3953 (42.0) 2408 (41.9) 1545 (42.2) 0.747 1154 (37.7) 1951 (43.7) 710 (46.6) 0.001
Fixed combinations 5410 (57.5) 3176 (55.3) 2234 (61.1) 0.001 1585 (51.8) 2657 (59.5) 986 (64.7) 0.001
Anticholinergics 
and short-acting 
β2-agonists
687 (7.3) 395 (6.9) 292 (8.0) 0.043 197 (6.4) 332 (7.4) 134 (8.8) 0.014
Inhaled steroids 
and long-acting 
β2-agonists
5155 (54.8) 3022 (52.6) 2133 (58.3) 0.001 1510 (49.3) 2525 (56.6) 950 (62.4) 0.001
Steroids 1865 (19.8) 899 (15.6) 966 (26.4) 0.001 359 (11.7) 949 (21.3) 479 (31.5) 0.001
Oral 701 (7.5) 226 (3.9) 465 (13.0) 0.001 99 (3.2) 318 (7.1) 251 (16.5) 0.001
Inhaled 1492 (15.9) 773 (13.5) 719 (19.7) 0.001 304 (9.9) 775 (176.4) 351 (23.0) 0.001
Antibiotics 4671 (49.7) 2752 (47.9) 1919 (52.5) 0.001 1462 (47.7) 2210 (49.5) 807 (53.0) 0.003
Abbreviations: COPD, chronic obstructive pulmonary disease.
Note: Percentages in parenthesis.
stage relates to changes in HRQL. Patients were recruited 
from those visited in the outpatient setting, mostly in 
primary care centers, and therefore may not represent the 
COPD population at large. It should be noted that 16% of 
our population were never smokers. These patients were 
not excluded because the objective of the study was to 
assess HRQL in outpatients with COPD attended by fam-
ily physicians and pneumologists in actual conditions of 
the daily practice. However, a diagnosis other than COPD 
cannot be excluded. In a recent multicenter study carried 
out in 9425 subjects with COPD recruited at 12 different 
sites worldwide, the percentage of never smokers varied 
between 3.1% and 9.4% in men and between 2.9% and 
11.2% in women (Buist et al 2007). On the other hand, 
other factors that may affect HRQL (eg, co-morbidity) were 
not evaluated. However, the large sample size strengths the 
ﬁ  ndings of our study.
In summary, this study shows the inﬂ  uence of female 
gender, older age and moderate-to-severe of airﬂ  ow limita-
tion on HRQL, particularly on the physical component of 
the SF-12 instrument, in patients with COPD attended in the 
outpatient setting in daily practice conditions.
Disclosure
A Martín is employed by Pﬁ  zer, Madrid, Spain. E Gobartt 
is employed by Boehringer Ingelheim España, Madrid, 
Spain. JM Rodríguez, JL Izquierdo, and P de Lucas have no 
conﬂ  icts of interest.International Journal of COPD 2008:3(4) 692
Martín et al
Acknowledgements
Presented in part as poster presentation at the Annual 
Congress of the European Respiratory Society, Munich, 
Germany, September 2–6, 2006. The authors are indebted to 
members of the VICE Study for the recruitment of patients, 
to Immaculada Vilardaga, Euroclin Institute, Barcelona, for 
his contribution to the statistical analysis and to Marta Pulido, 
MD, for editing the manuscript and editorial assistance.
References
Alonso J, Prieto L, Ferrer M, et al. 1998a. Testing the measurement proper-
ties of the Spanish version of the SF-36 Health Survey among male 
patients with chronic obstructive pulmonary disease. Quality of Life 
in COPD Study Group. J Clin Epidemiol, 51:1087–94.
Alonso J, Regidor E, Barrio G, et al. 1998b. [Population reference values 
of the Spanish version of the Health Questionnaire SF-36.] Med Clin 
(Barc), 111:410–6.
Antonelli-Incalzi R, Imperiale C, Bellia V, et al; the SaRA investigators. 
2003. Do GOLD stages of COPD severity really correspond to differ-
ences in health status? Eur Respir J, 22:444–9.
Barberà JA, Peces-Barba G, Agustí AGN, et al. 2001. Sociedad Española 
de Neumología y Cirugía Torácica (SEPAR): Guía para el diagnósticoy 
tratamiento de la enfermedad pulmonar obstructiva crónica. Arch 
Bronconeumol, 37:297–316.
Bestall JC, Paul EA, Garrod R, et al. 1999. Usefulness of the Medical 
Research Council (MRC) dyspnoea scale as a measure of disability in 
patients with chronic obstructive pulmonary disease. Thorax, 54:581–6.
[BTS] British Thoracic Society. 1997. BTS guidelines for the management 
of chronic obstructive pulmonary disease. The COPD Guidelines Group 
of the Standards of Care Committee of the BTS. Thorax, 52(Suppl 5):
S1–S28.
Buist AS, McBurnie MA, Vollmer WM, et al; on behalf of the BOLD 
Collaborative Research Group. 2007. International variation in the 
prevalence of COPD (the BOLD Study): a population-based prevalence 
study. Lancet, 370:741–50.
Burge PS, Calverley PM, Jones PW, et al. 2000. Randomised, double 
blind, placebo controlled study of ﬂ  uticasone propionate in patients 
with moderate to severe chronic obstructive pulmonary disease: the 
ISOLDE trial. BMJ, 320:1297–303.
Carrasco Garrido P, de Miguel Díez J, Rejas Gutiérrez J, et al. 2006. Nega-
tive impact of chronic obstructive pulmonary disease on the health-
related quality of life of patients. Results of the EPIDEPOC study. 
Health Qual Life Outcomes, 4:31.
Chan-Yeung M, Ait-Khaled N, White N, et al. 2004. The burden and impact 
of COPD in Asia and Africa. Int J Tuberc Lung Dis, 8:2–14.
de Torres JP, Casanova C, Hernández C, et al. 2006. Gender associated 
differences in determinants of quality of life in patients with COPD: a 
case series study. Health Qual Life Outcomes, 4:72.
Decramer M, De Benedetto F, Del Ponte A, et al. 2005. Systemic effects 
of COPD. Respir Med, 99:S3–S10.
Domingo-Salvany A, Lamarca R, Ferrer M, et al. 2002. Health-related 
quality of life and mortality in male patients with chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med, 166:680–5.
Ferrer M, Alonso J, Morera J, et al. 1997. Chronic obstructive pulmonary 
disease stage and health-related quality of life. Ann Intern Med, 
127:1072–9.
Gallego MC, Samaniego J, Alonso J, et al. 2002. [Dyspnea in COPD: relation 
to the MRC scale with dyspnea induced by walking and cardiopulmo-
nary stress testing.] Arch Bronconeumol, 38:112–6.
Garratt AM, Hutchinson A, Russell I. 2000. Patient-assessed measures of 
health outcome in asthma: A comparison of four approaches. Respir 
Med, 94:597–606.
Hajiro T, Nishimura K, Tsukino M, et al. 2000. Stages of disease severity 
and factors that affect the health status of patients with chronic obstruc-
tive pulmonary disease. Respir Med, 94:841–6.
Halbert RJ, Isonaka S, George D, et al. 2003. Interpreting COPD prevalence 
estimates: what is the true burden of disease? Chest, 123:1684–92.
Halbert RJ, Natoli JL, Gano A, et al. 2006. Global burden of COPD: 
systematic review and meta-analysis. Eur Respir J, 28:523–32.
Hilleman DE, Dewan N, Malesker M, et al. 2000. Pharmacoeconomic 
evaluation of COPD. Chest, 118:1278–85.
Hurst JR, Wilkinson TMA, Donaldson GC, et al. 2004. Upper airway 
symptoms and quality of life in chronic obstructive pulmonary disease 
(COPD). Respir Med, 98:767–70.
Katsura H, Yamada K, Kida K. 2005. Both generic and disease speciﬁ  c 
health-related quality of life are deteriorated in patients with under-
weight COPD. Respir Med, 99:624–30.
Katz PP, Eisner MD, Yelin EH, et al. 2005. Functioning and psychological 
status among individuals with COPD. Qual Life Res, 14:1835–43.
Mahler DA. 2000. How should health-related quality f life be assessed in 
patients with COPD? Chest, 117:54S–57S.
Manino DM. 2005. Epidemiology and global impact of chronic obstructive 
pulmonary disease. Semin Respir Crit Care Med, 26:204–10.
Miravitlles M, Alvarez-Sala JL, Lamarca R, et al; IMPAC Study Group. 
2002. Treatment and quality of life in patients with chronic obstructive 
pulmonary disease. Qual Life Res, 11:329–38.
Miravitlles M, Calle M, Alvarez-Gutierrez F, et al. 2006. Exacerbations, 
hospital admissions and impaired health status in chronic obstructive 
pulmonary disease. Qual Life Res, 15:471–80.
Miravitlles M, Ferrer M, Pont A, et al; IMPAC Study Group. 2004. Effect 
of exacerbations on quality of life in patients with chronic obstructive 
pulmonary disease: a 2 year follow up study. Thorax, 59:387–95.
Pauwels RA, Rabe KF. 2004. Burden and clinical features of chronic obstruc-
tive pulmonary disease (COPD). Lancet, 364:613–20.
Peruzza S, Sergi G, Vianello A, et al. 2003. Chronic obstructive pulmonary 
disease (COPD) in elderly subjects: impact on functional status and 
quality of life. Respir Med, 97:612–7.
Reardon JZ, Lareau SC, ZuWallack R. 2006. Functional status and 
quality of life in chronic obstructive pulmonary disease. Am J Med, 
119(10 Suppl 1):32–7.
Sobradillo V, Miravitlles M, Jimenez CA, et al. 1999. [Epidemiological 
study of chronic obstructive pulmonary disease in Spain (IBERPOC): 
prevalence of chronic respiratory symptoms and airﬂ  ow limitation.] 
Arch Bronconeumol, 35:159–66.
Sobradillo-Peña S, Miravitlles M, Gabriel R, et al. 2000. Geographic 
variations in prevalence and underdiagnosis of COPD. Results of the 
IBERPOC multicentre epidemiological study. Chest, 118:981–9.
Ståhl E, Lindberg A, Jansson SA, et al. 2005. Health-related quality of life is 
related to COPD disease severity. Health Qual Life Outcomes, 3:56.
Viejo-Bañuelos JL, Pueyo-Bastida A, Fueyo-Rodríguez A. 2006. Char-
acteristics of outpatients with CPD in daily practice: The E4 Spanish 
Project. Respir Med, 100:2137–43.
Vilagut G, Ferrer M, Rajmil L, et al. 2005. [The Spanish version of the Short 
Form 36 Health Survey: a decade of experience and new developments.] 
Gat Sanit, 19:135–50.
Villasante Fernandez-Montes C. 1999. [IBERPOC: an evaluation of the 
results. The Scientiﬁ  c Committee of the IBERPOC Study.] Arch 
Bronconeumol, 35(Suppl 3):40–3.
Ware J Jr, Kosinski M, Keller SD. 1996. A 12-item Short-Form Health 
Survey: construction of scales and preliminary tests of reliability and 
validity. Med Care, 34:220–33.
Weiss ST, DeMeo DL, Postma DS. 2003. COPD: problems in diagnosis 
and measurement. Eur Respir J, 21(Suppl 41):4s–12s.
Wijnhoven HAH, Kriegsman DMW, Hesselink AE, et al. 2003. The inﬂ  u-
ence of co-morbidity on health-related quality of life in asthma and 
COPD patients. Respir Med, 97:468–75.